Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Toronto

$135,000.00

Global proteomic, chemical genomic, and phenotypic analyses of Hsp90 co-chaperones and client proteins involved in Candida albicans development, drug resistance, and pathogenesis.

EF 2014-15

Résumé
Due to the rise in the prevalence of immunocompromised and hospitalized patients, there is an increasing population of individuals that are highly susceptible to invasive infections by fungal pathogens. The major cause of nosocomial fungal infections is Candida albicans, which accounts for 9-12% of all hospital- acquired infections and has an attributable mortality rate of 38% despite significant advances in diagnosis and increased use of antifungal therapies. Treatment is hampered by a limited number of antifungal drugs and by drug resistance, demanding development of new therapeutic approaches. Hsp90 is a molecular chaperone that acts to stabilize components of signal transduction cascades that are vital in allowing this fungus to cause disease. In C. albicans, Hsp90 is a key regulator of adaptation to host stresses and morphogenesis, both of which are required for pathogenesis. Targeting Hsp90 is a powerful strategy to treat fungal infections; however, current Hsp90 inhibitors affect both pathogen and host Hsp90 proteins, leading to toxic side-effects. Therefore, clinical antifungal utility depends upon identifying components of the Hsp90 chaperone network that can be selectively targeted in the pathogen. To identify and characterize elements of this chaperone network, I will perform the first global proteomic and genomic analyses of Hsp90 interacting proteins under virulence-relevant environmental stresses. I will also perform chemical genomic analysis to define the role of Hsp90 in morphogenesis. By identifying Hsp90 interacting proteins in C. albicans, we will define a set of potential antifungal drug targets. Additionally, Hsp90 plays a central role in many oncogenic processes in humans, thus the knowledge gained from examining both physical and genetic Hsp90 interactions in this fungal pathogen and defining conserved elements may also illuminate potential therapeutic options for cancer.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
319437
Name
O'Meara Teresa R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Global proteomic, chemical genomic, and phenotypic analyses of Hsp90 co-chaperones and client proteins involved in Candida albicans development, drug resistance, and pathogenesis.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antifungal Therapies; Candida Albicans; Chaperone Proteins; Drug Resistance; Evolution; Genomics; Hsp90; Morphology; Pathogenesis; Proteomics
Abstract
Due to the rise in the prevalence of immunocompromised and hospitalized patients, there is an increasing population of individuals that are highly susceptible to invasive infections by fungal pathogens. The major cause of nosocomial fungal infections is Candida albicans, which accounts for 9-12% of all hospital- acquired infections and has an attributable mortality rate of 38% despite significant advances in diagnosis and increased use of antifungal therapies. Treatment is hampered by a limited number of antifungal drugs and by drug resistance, demanding development of new therapeutic approaches. Hsp90 is a molecular chaperone that acts to stabilize components of signal transduction cascades that are vital in allowing this fungus to cause disease. In C. albicans, Hsp90 is a key regulator of adaptation to host stresses and morphogenesis, both of which are required for pathogenesis. Targeting Hsp90 is a powerful strategy to treat fungal infections; however, current Hsp90 inhibitors affect both pathogen and host Hsp90 proteins, leading to toxic side-effects. Therefore, clinical antifungal utility depends upon identifying components of the Hsp90 chaperone network that can be selectively targeted in the pathogen. To identify and characterize elements of this chaperone network, I will perform the first global proteomic and genomic analyses of Hsp90 interacting proteins under virulence-relevant environmental stresses. I will also perform chemical genomic analysis to define the role of Hsp90 in morphogenesis. By identifying Hsp90 interacting proteins in C. albicans, we will define a set of potential antifungal drug targets. Additionally, Hsp90 plays a central role in many oncogenic processes in humans, thus the knowledge gained from examining both physical and genetic Hsp90 interactions in this fungal pathogen and defining conserved elements may also illuminate potential therapeutic options for cancer.
Competitiondate
201411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
O'Meara, Teresa R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~